[New drug treatment for age-related macular degeneration].
New drugs for age-related macular degeneration present a major advance in the treatment of the most common cause of blindness in Iceland. Vascular endothelial growth factor antibodies reduce the risk of blindness and improve vision in patients with age-related macular degeneration.
Stefánsson
Einar
E
Laeknalid Háskóla Islands. einarste@landspitali.is
la Cour
Morten
M
Helgadóttir
Gudleif
G
Sigurdsson
Haraldur
H
Jónasson
Fridbert
F
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007267:Injections / Q000379:methods; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000378:metabolism; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab